Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Innovation And Structural Change In Pharmaceuticals And Biotechnology

H. Grabowski, J. Vernon
Published 1994 · Business

Save to my Library
Download PDF
Analyze on Scholarcy
Share



This paper is referenced by
10.1515/jbnst-2014-2-310
Innovation and Market Structure in Pharmaceuticals: An Econometric Analysis on Simulated Data
C. Garavaglia (2014)
10.1007/978-3-540-24823-1_4
Networked Alliances and Innovation
L. Suarez-Villa (2002)
10.1080/1355297X.2004.11736241
Abstract
F. Gino (2004)
Towards a History Friendly Model of Innovation, Market Structure and Regulation in the Dynamics of the Pharmaceutical Industry: the Age of Random Screening
F. Malerba (2001)
Appendix : Therapeutic Classes in the Pharmaceutical Industry
C. Matraves (1998)
10.1017/cbo9781107280120
Innovation and the Evolution of Industries: History-Friendly Models
F. Malerba (2016)
10.1080/758519309
R&d Costs, Innovative Output and Firm Size in the Pharmaceutical Industry
J. DiMasi (1995)
10.5912/JCB735
Business Model Innovation Opportunities for the Biopharmaceutical Industry: A Systematic Review
James B. Downs (2016)
10.3917/REOF.096.0157
Biotechnologies et industrie pharmaceutique. Un modèle évolutionnaire conforme à l'histoire
F. Malerba (2006)
Intangible Assests and Market Value: Evidence from Biotechnology Firms
L. Nesta (2003)
10.1504/IJBT.2003.004104
The collaborative economy of biotechnology: alliances, outsourcing and R&D
L. Suarez-Villa (2003)
10.1109/PICMET.2007.4349457
Cross-national and Cross-industrial Comparison of Two Strategy Approaches for Global Industrial Evolution
Chia-Han Yang (2007)
10.2165/00019053-200018001-00005
The Distribution of Sales Revenues from Pharmaceutical Innovation
H. Grabowski (2012)
10.1177/0891242402016002001
Analyzing an Innovative Environment: San Diego as a Bioscience Beachhead
S. Walcott (2002)
Corporate governance practices and companies' R&D orientation: Evidence from European countries. Bruegel Working Paper 2011/01, 24 January 2011
B. V. Pottelsberghe (2011)
Innovation and competitiveness in European biotechnology
Fabio Pammolli (2002)
10.1023/A:1011144517789
Innovation and Merger Decisions in the Pharmaceutical Industry
E. Morgan (2001)
10.2139/ssrn.1983256
The Impact of Public Basic Research on Industrial Innovation: Evidence from the Pharmaceutical Industry
Andrew A. Toole (2011)
Innovation Networks in the Biotechnology-Based Sectors
A. Pyka (2001)
Managing New Product Development Projects in a Competitive Market
Issariya Sirichakwal (2013)
Global Competitiveness in Pharmaceuticals: A European Perspective
A. Gambardella (2000)
10.1016/J.HLPT.2018.10.001
The relationship between medical innovation and health expenditure before and after health reform
S. Cinaroglu (2018)
10.1111/0017-4815.00173
Growing Global: Learning Locations in the Life Sciences
S. Walcott (2001)
10.1080/00076791.2014.975119
The evolution of the pharmaceutical industry
F. Malerba (2015)
10.2139/ssrn.2147797
La gestione strategica delle innovazioni biotecnolgiche: trade-off tra integrazioni aziendali e accordi interaziendali
Alessandro Basile (2012)
10.1080/1366271032000141643
KNOWLEDGE DYNAMICS: BIOTECHNOLOGY’S INCURSION INTO THE PHARMACEUTICAL INDUSTRY
M. Quéré (2003)
10.1080/1043859042000228679
Knowledge dynamics, firm strategy, mergers and acquisitions in the biotechnology based sectors
P. Saviotti (2005)
10.1080/1463677042000237062
Genomics, ICT and the formation of R&D networks
P. Groenewegen (2004)
10.3917/reof.073.85
On the Life Cycle of Knowledge Intensive Sectors
Thomas Grebel (2006)
10.1504/IJEIM.2005.006337
The evolution of R&D networking in the biotech industries
A. Pyka (2005)
The UK Biotech Sector and Brexit: Past Performance and Future Prospects
G. Owen (2018)
10.1504/IJBT.2008.021309
Genomics-based drug innovation: visions and commercial viability
A. Kraft (2008)
See more
Semantic Scholar Logo Some data provided by SemanticScholar